| 强直性脊柱炎的治疗 |
| |
| 引用本文： | 文琼芳,黄 烽. 强直性脊柱炎的治疗[J]. 临床荟萃, 2016, 31(5): 465. DOI: 10.3969/j.issn.1004-583X.2016.05.001 |
| |
| 作者姓名： | 文琼芳 黄 烽 |
| |
| 作者单位： | 解放军总医院 风湿科,北京 100853 |
| |
| 基金项目： | 国家科技部”十二五”支撑计划:AS的临床诊治技术研究(2014BAI07B00);国家科技部973项目:AS发生机制及控制策略研究(2014BA107B00) |
| |
| 摘 要： | 强直性脊柱炎(AS)是一种主要累及中轴骨骼和肌腱附着点的慢性炎症性疾病。随着对AS病因及发病机制的研究深入,AS诊断和治疗进展迅速。传统治疗药物的规范化治疗、新型治疗药物尤其是肿瘤坏死因子α (TNF-α)抑制剂的出现,正在改写AS药物治疗历史。早期、足量、规律药物治疗和功能锻炼是迅速抑制炎症、延缓新骨形成和影像学进展的重要方法。新型生物制剂治疗的有效性和安全性有待进一步研究证实。
|
| 关 键 词： | 脊柱炎 强直性 物理治疗技术 生物制剂 肿瘤坏死因子&alpha |
Current treatment and future progress of ankylosing spondylitis |
| |
| Wen Qiongfang,Huang Feng. Current treatment and future progress of ankylosing spondylitis[J]. Clinical Focus, 2016, 31(5): 465. DOI: 10.3969/j.issn.1004-583X.2016.05.001 |
| |
| Authors: | Wen Qiongfang Huang Feng |
| |
| Affiliation: | Department of Rheumatology，Chinese PLA General Hospital，Beijing 100853，China |
| |
| Abstract: | Ankylosing spondylitis (AS) is a chronic， progressive， inflammatory disorder that mainly affects axial skeleton. Researches of the etiology and pathogenesis of AS in the past years greatly contributed to the rapid progress in diagnosis and treatment. Meanwhile， the combination of standardized use of traditional agents and TNF alpha inhibitors has rewritten the medical history of AS. Early， adequate and regular therapy and functional exercise can inhibit inflammation， delay the radiographic progression and new bone formation immediately. Further studies are required to confirm the efficacy and safety of novel biological agents. |
| |
| Keywords: | spondylitis ankylosing physical therapy modalities； biological agents tumor necrosis factor alpha |
| 本文献已被 CNKI 等数据库收录！ |
| 点击此处可从《临床荟萃》浏览原始摘要信息 |
|
点击此处可从《临床荟萃》下载全文 |
